South Korea Post-Market Compliance Calendar: Managing Overlapping Regulatory Timelines
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Post-market compliance in South Korea is not a set of isolated deadlines but several overlapping cycles: item renewal every 5 years, a KGMP certificate valid for 3 years with the periodic review application due 90 days before expiry, and UDI data changes that must be modified within 10 days. If any one line falls behind, it pulls on the others.
- Consolidating onto one calendar sheet makes collisions surface early. The KGMP expiry, an item entering its renewal window, and UDI data unmaintained after a site change — each has an owner, yet nobody sees them collide.
- The driver is Article 49 of the Medical Devices Act: Act No. 17248, promulgated April 7, 2020 and effective October 8, 2020, put the six certificate types on a 5-year cycle; the first batch of new certificates thus enters the first concentrated expiry window from October 2025. This date is derived from the statutory starting point and is verifiable.
2. Legal basis
The following instruments supply the cycles, deadlines and reporting duties tracked on the calendar.
| Medical Devices Act / 의료기기법 | Act No. 17248 (2020 amendment) | Amended and promulgated April 7, 2020, effective October 8, 2020 | Article 49 (item renewal, 5-year cycle); Article 31(1) (management of side effects, recall); Article 31-2 (supply details reporting); Article 8(1) (post-market study); Article 25 (self-regulatory review of advertising) |
| Standards for Medical Device Manufacture and Quality Management / 의료기기 제조 및 품질관리 기준 (KGMP) | MFDS Notice No. 2023-79 | 2023 | Mandatory for classes 2 to 4; certificate valid 3 years; periodic review application due 90 days before expiry |
| Regulations on Medical Device Standard Codes / 의료기기 표준코드 표시 및 관리요령 | MFDS Notice No. 2020-29 | June 12, 2020 | UDI database submission items and procedures; modification within 10 days after information changes |
| Medical Devices Act Enforcement Rule / 의료기기법 시행규칙 | Prime Ministerial Decree No. 2127 | Partially amended, promulgated and effective July 1, 2026 | Article 51(1) (three adverse event reporting tiers of 7 days, 15 days and 30 days); Article 54-2 (distribution record reporting, applied by class across four year-milestones) |
Template of the South Korean post-market compliance calendar
| Cycle | Compliance item | Legal basis | Preparation lead time | Responsible entity |
| 5 years | Item renewal (all 6 types across manufacturing/import licence, certification and notification) | Medical Devices Act Article 49 (Act No. 17248) | Start 180 days before expiry (practical estimate; subject to the acceptance requirements in force at the time) | Licence holder primarily |
| 3 years | KGMP periodic review | MFDS Notice No. 2023-79 | Apply 90 days before expiry | Manufacturing site plus licence holder |
| Within 10 days after a change | UDI data modification (IMDIS) | MFDS Notice No. 2020-29 | Register immediately after the change and submit within 10 days | Licence holder |
| By reporting cycle (practical estimate) | Distribution record reporting to IMDIS | Medical Devices Act Article 31-2; Enforcement Rule Article 54-2 | By class: class 4 from July 1, 2020; class 3 from July 1, 2021; class 2 from July 1, 2022; class 1 from July 1, 2023 | Licence holder and business operators |
| Not less than 4 years and not more than 7 years after marketing (statutory range; specific period determined by the Minister) | Post-market study (formerly re-examination) | Medical Devices Act Article 8(1) and (2) | Counted from the approval effective date; first confirm the period determined by the Minister | Licence holder plus manufacturer |
| Notice of the competent authority | Re-evaluation | Medical Devices Act Article 9 | Submit within the specified period after receiving the notice | Licence holder responds on a unified basis |
| Event-triggered | Adverse event reporting and record keeping | Medical Devices Act Article 31(1); Enforcement Rule Article 51(1) | Death and life-threatening cases within 7 days (details within 8 days of the first report date); hospitalisation or extended hospitalisation, irreversible severe disability or functional impairment, and congenital malformations within 15 days; other abnormal cases and foreign government measures within 30 days | Each node of the operator chain |
| Event-triggered | Recall and submission of a recall plan | Medical Devices Act Article 31(2) and (3) | Initiated immediately upon discovering a situation hazardous to health | Licence holder submits, manufacturer executes |
| Before publication | Self-regulatory advertising review (conducted by self-regulatory review institutions) | Medical Devices Act Article 25 | Complete review before finalising materials; no statutory review processing period; review validity 3 years | Licence holder |
| Continuous | Records for tracked devices | Medical Devices Act and Enforcement Rule provisions | Continuous recording per the type list annexed to the current notice | Business operators plus terminal institutions |
Note: distribution record reporting frequency follows the current notices and IMDIS requirements; the post-market study period is the statutory range of not less than 4 years and not more than 7 years after marketing, with the specific period determined by the Minister, and the approval notice governs each case.
3. Expert insights
Insight 1: the cycles are deliberately staggered, so collision years are inevitable.
The least common multiple of the 5-year, 3-year and 10-day cycles far exceeds any planning horizon, and overlapping years appear every few years. Collisions are inevitable, so the focus shifts to the handling order: hard deadlines first, items with discretionary slack after.
Insight 2: KGMP is the precondition hidden behind item renewal.
An expired KGMP certificate drags on licence-type renewals, and the 3-year and 5-year cycles are not synchronised. Consolidate on one sheet with a linked alert treating KGMP validity as an input to item renewal, as described in the guide on the KGMP certificate.
Insight 3: immediate duties like the 10-day rule are the ones organisations forget.
Long-cycle duties usually have watchers; event-triggered duties like the 10-day modification are easily missed because the clock starts at the change, not on a calendar day. Insert a gate: before any licence information change is closed, confirm the IMDIS update is scheduled.
Insight 4: the calendar must be maintained by a single owner.
When several lines are scattered across the licence holder, registration, quality and logistics teams, every local sheet is correct but the combination is wrong. Designate a single maintainer, others only feeding change information — an action to write into the licence holder service deliverables.
4. Practical recommendations
- Build one sheet before discussing division of work. Create the ledger on this guide’s template with fields for item name, certificate type, effective date, expiry date and each cycle’s next milestone; for items with no actual import record during validity, consider giving up renewal, as described in the guide on item renewal.
- Set two alert levels. Set internal alerts at 12 and 6 months before the expiry month (an internal position): the first starts preparation, the second locks the submission date.
- Turn event-triggered duties into process gates. Embed an IMDIS data update check in each of the change, recall and adverse event processes, with the data definitions described in the guide on distribution record reporting and supply details reporting.
- Designate a single maintainer and archive quarterly reviews. At least two people: one maintains the calendar, one reviews quarterly; the review conclusions go in writing, covering gaps, corrections and the next review date.
- Write the licence holder’s deliverables into the agreement. State in the KLH agreement the duties and deadlines for calendar maintenance and submission on the company’s behalf.
5. Verification checklist
- □ Cycle definitions: check the sources of the 5-year (Article 49), 3-year and 10-day positions; all three cycle sources are available and practical estimate items are marked.
- □ Expiry date coverage: check the list across the six certificate types; every item has an expiry date.
- □ Lead time: check the two internal start points of 180 days and 90 days; lead time is no shorter than the specified values and appears on the calendar.
- □ UDI change gate: sample the IMDIS update step in the change process; every change triggers the modification within 10 days.
- □ Distribution reporting start dates: check each item’s class against the four year-milestones; all items have passed their applicable dates with no class mismatches.
- □ Regression check: verify that the post-market study and re-evaluation milestones are on the sheet; both tracks have an alert mechanism.
- □ Owner and review records: check the maintainer and quarterly reviewer, sample the last four review records; at least two people with duties assigned, records covering gaps, corrections and the next date.
Regulatory information verified as of October 29, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, Korean licence holder and local testing support for the Republic of Korea. Our team manages adverse event reporting and recall coordination with MFDS, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us